 |
|
Sign in to view your progression
|
|
LIVE SESSION
Debate 2: First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer - Pro/Con
|
|
|
ON-DEMAND
First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer- Pro/Con
|
|
{{ help_message }}
{{filter}}